TRBC1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Given TRBC1 targeting excludes a substantial number of patients to be eligible, the development of TRBC2-targeting CAR-T cell therapy is also currently underway for TRBC2-positive PTCL tumors [152].